The U.S. Pain Foundation recently submitted comments to the Food and Drug Administration (FDA) in response to its request for Guidance for Industry Comments to the Docket regarding the Development of Non-Opioid Analgesics for Acute Pain.
Recent Posts
- Morgan’s Wonderland Camp To Welcome ‘Pain Warriors’ From All Across United States, June 19-23
- Join U.S. Pain Foundation as we tell Congress that Pain Care Needs More Options – Virtual Advocacy Day 2022
- U.S. Pain Foundation’s Docket Comments to the FDA on the Development of Non-Opioid Analgesics for Acute Pain
- U.S. Pain Foundation’s Comments on the 2022 Revised Draft CDC Clinical Practice Guideline for Prescribing Opioids
- U.S. Pain Foundation launches 2022 Chronic Pain Community Survey